Compare CIM & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | MNKD |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2007 | 2004 |
| Metric | CIM | MNKD |
|---|---|---|
| Price | $8.33 | $3.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $14.17 | $8.08 |
| AVG Volume (30 Days) | 1.4M | ★ 3.3M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 21.33% | N/A |
| EPS Growth | ★ 56.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $26.63 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $8.11 | $2.23 |
| 52 Week High | $14.18 | $6.51 |
| Indicator | CIM | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 61.07 |
| Support Level | $8.11 | $3.24 |
| Resistance Level | $13.82 | $4.28 |
| Average True Range (ATR) | 0.25 | 0.15 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 37.14 | 95.65 |
Chimera Investment Corporation is an internally managed REIT whose principal business objective is to provide attractive risk-adjusted returns and distributable income through investment performance linked to mortgage credit fundamentals. Through its mortgage lending, investment management, and advisory services platforms, the Company operates as a fully integrated mortgage business that originates, manages, and invests in a diversified range of mortgage assets. The Company invests, directly or indirectly, generally on a levered basis across a spectrum of mortgage assets, including residential mortgage loans, Non-Agency RMBS, Agency RMBS, Agency CMBS, MSRs, business purpose and investor loans, including RTLs, and other real estate-related assets.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.